Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2202 - Programmed death-ligand 1 (PD-L1) and immune infiltrates are prognostic for better outcome and enriched in the ATM (ataxia telangiectasia mutated)-low segment of gastric cancer (GC)


08 Oct 2016


Poster Display


Elaine Kilgour


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


E. Kilgour1, H. Angell2, K. Kim3, S. Ahn3, S.T. Kim4, A. Sharpe5, J. Ogden2, A. Davenport6, J.C. Barrett7, D. Hodgson1, J. Lee4

Author affiliations

  • 1 Oncology Translational Science, AstraZeneca, SK10 4TG - Macclesfield/GB
  • 2 Oncology Translational Science, AstraZeneca, Cambridge/GB
  • 3 Pathology And Translational Genomics, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul/KR
  • 4 Division Of Hematology-oncology, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul/KR
  • 5 Discovery Sciences, AstraZeneca, Cambridge/GB
  • 6 South Manchester, University Hospital, Manchester/GB
  • 7 Oncology Translational Science, AstraZeneca, Boston/US


Abstract 2202


In GC an urgent need exists for effective targeted therapies and predictive markers. In a PhII study, low ATM expression in tumour was associated with greater overall survival (OS) benefit in GC patients treated with olaparib/paclitaxel (1). Antibodies targeting the programmed death-1 checkpoint have reported clinical efficacy in GC, with tumour PD-L1 expression and microsatellite instability (MSI) emerging as predictive markers. We have assessed the prognostic significance of PD-L1 and immune infiltrates in GC and their association with the ATM-low segment.


PD-L1, CD3+ T-lymphocytes, CD8+ cytotoxic T-cells, human epidermal growth factor receptor 2 (HER2) and ATM expression were assessed by immunohistochemistry (IHC) in a cohort of 384 Korean gastric cancers.


PD-L1 positivity (>0%) on tumour cells (TC) and immune infiltrates (IC) was 16% and 90% respectively and a correlation was observed with MSI (p 


In GC PD-L1, CD3/CD8 are prognostic for better outcome. Mutually exclusive ATM-low and HER2-high segments differ in their immune profile, with the “immunologically hot” ATM-low segment enriched for MSI, PD-L1 and CD3/8. This illustrates the opportunity to employ different strategies for maximising the benefit from immune therapies in HER2 vs ATM segments. (1) Bang et al, (2015) JCO 33:3858-3865

Clinical trial identification

Legal entity responsible for the study

AstraZeneca and Samsung Medical Center




E. Kilgour, H. Angell: Employee and holds stock in AstraZeneca

A. Sharpe, J. Ogden, J.C. Barrett, D. Hodgson: AstraZeneca employee and stockholder

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings